Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: ROIV) | Delayed: 38.23 +2.19 (6.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.04 | 52 Week High | $ | |||
| Open | $36.62 | 52 Week Low | $ | |||
| Day High | $38.52 | P/E | N/A | |||
| Day Low | $35.71 | EPS | $ | |||
| Volume | 11,665,368 | |||||
